Targeted therapies in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia

This publication has 14 references indexed in Scilit:

• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
  Blood, 2002
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
  Blood, 2002
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
  Blood, 2002
• Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis
  Blood, 2002
• Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemias
  Seminars in Oncology, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
  New England Journal of Medicine, 2001
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
  Proceedings of the National Academy of Sciences, 1990
• Acute leukaemia in bcr/abl transgenic mice
  Nature, 1990
• Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome
  Science, 1990